Immune response in relation to clinical outcome
To search for immune surrogate markers of clinical efficacy, we looked for the association between remaining C-peptide secretion at 15 months (Immune responses in GAD-alum treated patients in relation to Clinical outcome. Patients who received GAD-alum were stratified into Good Responders (GR, n=23, loss < 30% AUC) and Poor Responders (PR, n=32, loss ≥ 30% AUC) according to their C-peptide preservation at 15 months. Comparison of the immunological data between GR and PR revealed that GADTo further search for signatures related to the presence or absence of DR3DQ2 haplotype, GR and PR were stratified according to their haplotype (